GLOBIN Study Reports Promising First-Line Outcomes in Follicular Lymphoma
Key Clinical Summary
- A first-line chemo-free regimen combining glofitamab and obinutuzumab achieved a 100% objective response rate and 88% complete metabolic response in high-tumor burden follicular lymphoma.
- Eight-month progression-free survival reached 95%, with no deaths reported at a median 7.6-month follow-up.
- Cytokine release syndrome (CRS) was mostly low grade, suggesting obinutuzumab pre-treatment may mitigate toxicity risks.
Glofitamab plus obinutuzumab (GLOBIN) demonstrated promising efficacy and manageable safety as first-line therapy for high-tumor burden follicular lymphoma, according to phase II multicenter trial results presented at the 67th American Society of Hematology (ASH) Annual Meeting and published in Blood.
Study Findings
The phase II GLOBIN trial enrolled 35 previously untreated patients with grade 1-3A follicular lymphoma requiring therapy based on modified GELF criteria. Participants received 4 weekly doses of obinutuzumab followed by step-up dosing of glofitamab, with treatment continuing for up to 12 cycles.
Among 34 response-evaluable patients, the objective response rate reached 100% (95% CI, 90%-100%), and the complete metabolic response rate was 88% (95% CI, 73%-97%). With a median follow-up of 7.6 months, the 8-month progression-free survival rate was 95%, and no deaths were reported.
Safety outcomes were favorable. CRS occurred in 40% of patients, predominantly grade 1 (37%); only one grade 3 event was observed and resolved rapidly with dexamethasone and tocilizumab. Infection rates were 31%, all grade 1-2. Other treatment-related adverse events included infusion reactions (49%), neutropenia (31%), fatigue (26%), and diarrhea (23%). No patients discontinued therapy because of adverse events.
Investigators concluded that pre-treatment with obinutuzumab appeared to reduce CRS risk while maintaining high response rates, supporting further exploration of this chemotherapy-free approach.
Clinical Implications
For clinicians and payers, these early data highlight the potential of bispecific antibody-based regimens to replace traditional chemoimmunotherapy in frontline treatment of high-tumor burden follicular lymphoma. Standard regimens are associated with prolonged immune suppression, infection risk, and secondary malignancies, underscoring the need for safer, time-limited alternatives.
The high response rates and manageable toxicity profile observed with GLOBIN may translate into improved quality of life and reduced long-term health care utilization. Reduced hospitalization for severe CRS or infections could influence cost-effectiveness analyses and payer coverage decisions, particularly as value-based oncology care models expand.
However, follow-up remains limited, and longer-term durability data will be essential before widespread adoption. Health systems should monitor evolving evidence and assess real-world feasibility, including infusion-related resource requirements and monitoring protocols.
Study authors reported that “[GLOBIN] has a manageable safety profile and is associated with high CMR rates among patients with previously untreated, high-tumor burden FL.” They added that obinutuzumab pre-treatment “appears to reduce the risk of CRS,” with no grade 2 cases and only one grade 3 event among 35 patients.
Conclusion
The phase II GLOBIN trial suggests that a chemo-free regimen combining glofitamab and obinutuzumab may provide effective first-line therapy for high-tumor burden follicular lymphoma with manageable toxicity. Ongoing follow-up and additional studies will determine long-term durability and potential impact on clinical practice and managed care strategies.
Reference
Merryman R, von Keudell G, Redd R, et al. Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: first results of a multicenter phase II trial. Presented at: ASH 2025; December 6-9; Orlando, FL.
